SCHEMBL6895646

SCHEMBL6895646

CCOC(=O)c1nc(-c2ccc(F)cc2)c(CCCl)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.58
TRPM8 Q7Z2W7 1/20 0.49
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 6/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 3/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.44
GRM6 O15303 1/20 0.44
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
MAPK14 Q16539 1/20 0.42
LMNA P02545 3/20 0.42
ALOX5 P09917 1/20 0.42
PRKCZ Q05513 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7462975 0.90 TRPM8 (0.47) PTGS2TRPM8KDM4EALDH1A1HPGD
SCHEMBL7462498 0.88 PTGS2 (0.58) PTGS2TRPM8KDM4EALDH1A1NPC1
SCHEMBL7457268 0.88 ALDH1A1 (0.52) TRPM8KDM4EALDH1A1NPC1RAB9A
SCHEMBL27428321 0.86 PTGS2 (0.43) PTGS2TRPM8KDM4EALDH1A1NPC1
SCHEMBL7459503 0.81 PTGDR2 (0.43) PTGDR2
SCHEMBL7458932 0.78 TRPM8 (0.47) PTGS2TRPM8KDM4EALDH1A1HPGD
SCHEMBL7457281 0.76 ALDH1A1 (0.52) TRPM8KDM4EALDH1A1NPC1RAB9A
SCHEMBL7462671 0.75 L3MBTL1 (0.46) TRPM8KDM4EALDH1A1HPGDMAPT
SCHEMBL6598899 0.75 PTGDR2 (0.43) PTGDR2
SCHEMBL1249510 0.75 ALDH1A1 (0.52) TRPM8KDM4EALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806275-B2 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION NIHON NOHYAKU CO., LTD. (JP) 2004-10-19 US disclosed
EP-0940401-B1 2-CARBONYLTHIAZOLE DERIVATIVES AND USE OF THE SAME TAISHO PHARMACEUTICAL CO LTD (JP) 2002-11-06 EP disclosed
US-20020156283-A1 Arylpiperidine derivatives and use thereof NIHON NOHYAKU CO., LTD. (JP) 2002-10-24 US disclosed
CN-1088707-C 2-carbonylthiazole derivatives and use thereof TAISHO PHARMACEUTICAL CO LTD (JP) 2002-08-07 CN disclosed
US-6407121-B1 DOPAMINE D4 RECEPTOR ANTAGONISTS; PSYCHOLOGICAL AND BRAIN DISORDERS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA; SIDE EFFECT REDUCTION NIHON NOHYAKU CO., LTD. (JP) 2002-06-18 US disclosed
EP-1070715-A1 ARYLPIPERIDINE DERIVATIVES AND USE THEREOF Nihon Nohyaku Co., Ltd. (JP) 2001-01-24 EP disclosed
US-6166033-A 2-carbonylthiazole derivatives and use of the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
CN-1237971-A 2-carbonylthiazole derivatives and use of the same TAISHO PHARMACEUTICAL CO LTD (JP) 1999-12-08 CN disclosed
EP-0940401-A1 2-CARBONYLTHIAZOLE DERIVATIVES AND USE OF THE SAME TAISHO PHARMACEUTICAL CO. LTD (JP) 1999-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156283-A1 Arylpiperidine derivatives and use thereof DRD1, DRD4, DRD2 PTGS2 2880/4885TRPM8 2892/4885KDM4E 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.